Endo completes Indevus Pharmaceuticals buyout
This article was originally published in Scrip
Endo Pharmaceuticals has completed its $370 million acquisition of Indevus Pharmaceuticals. Indevus' common stock stopped trading on March 23rd, 2009 around 11 weeks after the $4.50 per share bid was made (scripnews.com, January 6th, 2009). An additional $3.00 per share is dependent on regulatory and sales milestones.